Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of small cell lung cancer, large cell neuroendocrine cancer of the lung, neuroendocrine prostate cancer, poorly differentiated neuroendocrine cancer of the gut or pancreas, Merkel cell carcinoma, or another high-grade neuroendocrine tumor.
- Your cancer must be advanced or have spread, and you must have tried at least one standard treatment (for small cell lung cancer, this must include a platinum-based chemotherapy like carboplatin or cisplatin).
- You must have a tumor that shows DLL3 protein expression (confirmed by a test).
- You must have at least one measurable tumor (by CT or MRI scans).
- You must be in good physical condition (able to do light activities, ECOG 0 or 1).
- Your previous treatment side effects should have mostly resolved, except for hair loss or controlled hormone issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.